Sentien is a biotechnology firm developing cell-based blood conditioning therapies to restore balance to the immune systems of critically ill patients... Read more
Sentien is a biotechnology firm developing cell-based blood conditioning therapies to restore balance to the immune systems of critically ill patients... Read more
News
Sep 02, 2021
PRWeb
Press Release: Sentienbiotech : Sentien Biotechnologies Partners with BARDA to Evaluate High Dose Cohort in Phase 1/2 Trial of SBI-101 for Treatment of Acute Kidney Injury Associated with Sepsis
Mar 30, 2021
PRWeb
Press Release: Sentienbiotech : Sentien Biotechnologies Completes Enrollment of First Cohort in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19
Nov 23, 2020
PRWeb
Press Release: Sentienbiotech : Sentien Biotechnologies Announces First Subject Dosed in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19
Oct 08, 2020
Benzinga
Sentienbiotech: Sentien Biotechnologies-Led Team Awarded $2.4M Contract from the U.S. Department of Defense and the Medical Technology Enterprise Consortium
Aug 18, 2020
PRWeb
Press Release: Sentienbiotech : Sentien Biotechnologies Announces Open IND in Phase 1/2 Trial of SBI-101 for Patients with COVID-19
Jul 09, 2020
PRWeb
Press Release: Sentienbiotech : Sentien Biotechnologies Names Dr. Allen R. Nissenson as Chief Medical Officer
May 15, 2020
PRWeb
Press Release: Sentienbiotech : Sentien Biotechnologies Names Richard Ganz as Executive Chairman
Oct 12, 2018
BioPortfolio
Sentienbiotech: Sentien Biotechnologies Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13082018 Prices from USD $250
Jun 07, 2017
BioPortfolio
Sentien: Sentien Biotechnologies Inc. Announces Open Enrollment in Phase 12 Trial of SBI101 for Patients with Acute Kidney Injury
Apr 18, 2017
MassDevice
Sentien: Sentien launches trial for drug-device combo for treating acute kidney injury
Sentienbiotech Competitors
1
2
3
4
5
6
7
8
9
10